Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BD Gets First Partnered Assay Released For Open-Platform BD Max

This article was originally published in The Gray Sheet

Executive Summary

BD unveiled BD Max last year as the first fully-automated molecular diagnostics analyzer with an open platform, signaling plans for a smartphone-style “app” business model for molecular diagnostics.

Advertisement

Related Content

Assay As App? BD Launches BD Max With Open Platform "Smartphone" Model
BD Closes $275 Million HandyLab Buy; New HAI Platform Will Launch In 2011

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT031717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel